CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment

HIV-1 RT is one of the key enzymes in the duplication of HIV-1. Inhibitors of HIV-1 RT are classified as nonnucleoside RT inhibitors (NNRTIs) and nucleoside analogues. NNRTIs bind in a region not associated with the active site of the enzyme. Within the NNRTI category, there is a set of inhibitors commonly referred to as TIBO inhibitors. Fifty TIBO inhibitors were used in the work to build 3-D QSAR models. The two known crystal structures of complexes are used to investigate and validate the docking protocol. The results show that the docking simulations reproduce the crystal complexes very well with RMSDs of approximately 1 A and approximately 0.6 A for 1REV and 1COU, respectively. The alignment of molecules and "active" conformation selection are the key to a successful 3D-QSAR model by CoMFA. The flexible docking (Autodock3) was used on determination of "active" conformation and molecular alignment, and CoMFA and CoMSIA were used to develop 3D-QSAR models of 50 TIBOs in the work. The 3D-QSAR models demonstrate a good ability to predict the activity of studied compounds (r2 = 0.972, 0.944, q2 = 0.704, 0.776). It is shown that the steric and electrostatic properties predicted by CoMFA contours can be related to the binding structure of the complex. The results demonstrate that the combination of ligand-based and receptor-based modeling is a powerful approach to build 3D-QSAR models.

[1]  Ajay N. Jain Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[2]  R. Pauwels,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2. , 1991, Journal of medicinal chemistry.

[3]  Pierre L'Ecuyer,et al.  Implementing a random number package with splitting facilities , 1991, TOMS.

[4]  Marcela Madrid,et al.  Docking of non‐nucleoside inhibitors: Neotripterifordin and its derivatives to HIV‐1 reverse transcriptase , 2002, Proteins.

[5]  Prashant V Desai,et al.  Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies , 2003, Protein science : a publication of the Protein Society.

[6]  S. Hannongbua,et al.  Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis. , 2000, Journal of molecular graphics & modelling.

[7]  Jarmo Huuskonen QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..

[8]  R. Zauhar,et al.  Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.

[9]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[10]  E. Pedersen,et al.  Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom , 1999, Antiviral chemistry & chemotherapy.

[11]  Supa Hannongbua,et al.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors , 1999, J. Comput. Aided Mol. Des..

[12]  Bernard R Brooks,et al.  A core-weighted fitting method for docking atomic structures into low-resolution maps: application to cryo-electron microscopy. , 2003, Journal of structural biology.

[13]  M L Lamb,et al.  Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. , 2000, Protein engineering.

[14]  Li Wang,et al.  Hierarchy of protein assembly at the vertex ring domain for yeast vacuole docking and fusion , 2003, The Journal of cell biology.

[15]  E. Clercq,et al.  Antiviral therapy for human immunodeficiency virus infections. , 1995 .

[16]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[17]  Xiaomin Luo,et al.  Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. , 2002, Journal of Medicinal Chemistry.

[18]  S. Hughes,et al.  Retroviral reverse transcription and integration: progress and problems. , 1992, Annual review of cell biology.

[19]  Roger J.-B. Wets,et al.  Minimization by Random Search Techniques , 1981, Math. Oper. Res..

[20]  E. Arnold,et al.  HIV reverse transcriptase structure-function relationships. , 1991, Biochemistry.

[21]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[22]  D. Richman,et al.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[23]  M. Miranda,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. , 1991, Journal of medicinal chemistry.

[24]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.

[25]  Stanislav Miertus,et al.  Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. , 2002, Journal of medicinal chemistry.

[26]  S. Goff,et al.  Retroviral reverse transcriptase: synthesis, structure, and function. , 1990, Journal of acquired immune deficiency syndromes.

[27]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[28]  Erik De Clercq,et al.  Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues , 1999 .

[29]  Michael Wiese,et al.  Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4- dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: A molecular modeling study , 1999, J. Comput. Aided Mol. Des..

[30]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[31]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[32]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[33]  Ingo Muegge,et al.  3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method , 2001 .

[34]  J N Weinstein,et al.  Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. , 1995, Journal of medicinal chemistry.

[35]  A. Debnath,et al.  Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. , 1999, Journal of medicinal chemistry.

[36]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[37]  A. Debnath,et al.  Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. , 1994, Journal of medicinal chemistry.

[38]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[39]  C. Dominguez,et al.  HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.

[40]  Atul Purohit,et al.  Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. , 2003, Bioorganic & medicinal chemistry letters.

[41]  K. Andries,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo benzodiazepin-2(1H)-one (TIBO) derivatives , 1991 .

[42]  M J Kukla,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4. , 1995, Journal of medicinal chemistry.

[43]  Jared Spidel,et al.  Kinetic and docking studies of the interaction of quinones with the quinone reductase active site. , 2003, Biochemistry.

[44]  Opera Ti,et al.  3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994 .

[45]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[46]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[47]  A. Carotti,et al.  Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). , 1999, Bioorganic & medicinal chemistry.

[48]  R. Pauwels,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. , 1991, Journal of medicinal chemistry.

[49]  J L Sullivan,et al.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. , 1991, The Journal of infectious diseases.

[50]  Ricardo L. Mancera,et al.  A new quantum stochastic tunnelling optimisation method for protein–ligand docking , 2003 .

[51]  Margaret A. Johnson,et al.  A novel modeling protocol for protein receptors guided by bound-ligand conformation. , 2003, Biochemistry.

[52]  D I Stuart,et al.  Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. , 1999, Journal of medicinal chemistry.

[53]  Jianping Ding,et al.  Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. , 1996, Drug design and discovery.

[54]  L. Loeb,et al.  Human Immunodeficiency Virus Reverse Transcriptase , 1996, The Journal of Biological Chemistry.